BRADFORD PATRICIA A purchased $7K of PHIO

Phio Pharmaceuticals (PHIO) presented Phase 1b trial data for its cancer treatment PH-762 at the ASDS Annual Meeting. The study suggested PH-762 is well-tolerated and may offer a tissue-sparing neoadjuvant therapy for cutaneous carcinomas. A Phase 2b study is planned for 2027. According to the company, PH-762 could improve patient outcomes by shrinking tumors before surgery.

Phio Pharmaceuticals (NASDAQ:PHIO) will present Phase 1b trial data for PH-762, its INTASYL compound, at the SITC annual meeting. The study found the treatment well-tolerated for skin cancers, with a Phase 2b study planned for 2027. PH-762 targets the PD-1 gene in skin cancer.

Phio Pharmaceuticals reported Phase 1b results for PH-762, stating it was well-tolerated and potentially tissue-sparing. The company plans to start a Phase 2b study in the first half of 2027.

Phio Pharmaceuticals (PHIO) announced positive Phase 1b trial results for its skin cancer treatment PH-762, to be presented at the SITC meeting. The data suggests PH-762 may shrink tumors before surgery with a favorable safety profile, according to the company. A Phase 2b study is planned for 2027.

Phio Pharmaceuticals reported a wider net loss of $4.16M in 3Q 2026, up 73.9% YoY, due to increased R&D and regulatory costs. EPS was ($0.36). The company advanced PH-762 toward a Phase 2b study, with a 65% response rate in Phase 1b trials. Manufacturing of PH-762 drug substance began in 3Q 2026.

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatmen